Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 10;18(1):641.
doi: 10.1186/s12879-018-3572-0.

Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?

Shannon A Gunawardana  1 , Robert H Shaw  2
Affiliations
Review

Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?

Shannon A Gunawardana et al. BMC Infect Dis. .

Abstract

Background: Dengue Virus (DENV) and Zika Virus (ZIKV) are closely related flaviviruses, circulating in overlapping geographical regions. The recent ZIKV epidemic has been linked to an explosion in reports of microcephaly and neurological defects. It is conceivable that our knowledge of DENV might potentiate the development of a ZIKV vaccine due to the close phylogenetic relationship between these flaviviruses and cross-reactive antibodies, principally to the envelope protein (E protein). Alternatively, cross-reactive antibodies that are generated following vaccination or infection, might become damaging during subsequent infections.

Main body: The aims of this review are to collate and analyse data from a recent series of DENV-derived monoclonal antibody (mAb) panels from different research groups. These panels measured DENV-mAb activity against ZIKV in terms of antibody-dependent enhancement (ADE) and neutralisation. Methodology used across groups was compared and critiqued. Furthermore, the specific antibody targets on E protein were considered and their therapeutic potential evaluated. Shortcomings of hmAb panels suggest ADE may be over-estimated and neutralisation underestimated, as compared to clinical situations. It remains unknown whether preference of enhancement or neutralisation by antibodies to ZIKV E protein is dictated by quantitative aspects of antibody titre or epitope specific variation. Additionally, little is known about how duration between flavivirus reinfections affect secondary antibody response.

Conclusion: This review concludes that our current knowledge of cross-reactive antibodies to E protein is inadequate to anticipate the outcome of deploying an E protein based vaccine to regions co-infected by DENV and ZIKV.

Keywords: Antibody-dependent enhancement; Cross-neutralisation; Cross-reactive antibodies; Dengue virus; Envelope protein; Flavivirus; Vaccines; Zika virus.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

N/A for this correspondence.

Consent for publication

N/A for this correspondence.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Olagnier D, et al. Dengue virus Immunopathogenesis: lessons applicable to the emergence of Zika virus. J Mol Biol. 2016;428:3429–3448. doi: 10.1016/j.jmb.2016.04.024. - DOI - PubMed
    1. Bhatt S, et al. The global distribution and burden of dengue. Nature. 2013;496:504–507. doi: 10.1038/nature12060. - DOI - PMC - PubMed
    1. World Health Organization (WHO). Global Strategy for Dengue Prevention and Control, 2012–2020 In: WHO Press 2012 http://www.who.int/denguecontrol/9789241504034/en/. Accessed 8 Apr 2018.
    1. Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot D, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet. 2016;387(10033):2125–2132. doi: 10.1016/S0140-6736(16)00651-6. - DOI - PMC - PubMed
    1. Hammond SN, et al. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg. 2005;73:1063–1070. doi: 10.4269/ajtmh.2005.73.1063. - DOI - PubMed

MeSH terms